Back to compounds

COMPOUND PROFILE / COMBINATIONS

Tesamorelin + Ipamorelin.

Research draft

This entry combines tesamorelin and ipamorelin.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Identity and evidence review notes

Component references are background only. No directly matched controlled combination result was established in this pass.

Overview

This entry combines tesamorelin and ipamorelin.

CLASSIFICATIONCombinations
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCombination

Mechanism

Both can affect the GH axis through different upstream receptors.

Human research

Tesamorelin's approved disease-specific evidence does not establish the combination's benefit.

Preclinical & other research

Component models are background, not tests of a commercial stack.

Safety & unknowns

GH, IGF-1 and glucose-related effects may overlap; combined safety is not established.

Regulatory status

Egrifta's authorisation does not extend to this mixture.

Reported use & evidence

Research profile draft

The supplied Tesamorelin + Ipamorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds